| I-056 Marc Cerou A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy Wednesday 10:20-11:50 |
| I-056 Marc Cerou A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy Wednesday 10:20-11:50 |